Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.60 |
| ▸ | THRA | P10827 | 8/20 | 0.60 |
| ▸ | PCNA | P12004 | 7/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | RXRA | P19793 | 3/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238467 | 0.80 | THRB (0.73) | THRBTHRAPCNAPOLBHIF1A | |
| SCHEMBL16425259 | 0.80 | PCNA (0.68) | THRBTHRAPCNAPOLBHIF1A | |
| SCHEMBL12440046 | 0.78 | PCNA (0.69) | THRBTHRAPCNAPOLBHIF1A | |
| Thyropropic Acid SCHEMBL310201 | 0.74 | PCNA (1.00) | THRBTHRAPCNAPOLBHIF1A | |
| SCHEMBL2865530 | 0.73 | PCNA (0.66) | THRBTHRAPCNAPOLBHIF1A | |
| 3,5-Diiodothyropropionic Acid SCHEMBL1501771 | 0.73 | PCNA (1.00) | THRBTHRAPCNAPOLBHIF1A | |
| SCHEMBL6825994 | 0.72 | THRB (0.69) | THRBTHRAPCNAPOLBHIF1A | |
| SCHEMBL14485308 | 0.72 | PCNA (0.77) | THRBTHRAPCNAPOLBHIF1A | |
| SCHEMBL3686806 | 0.72 | THRA (0.82) | THRBTHRAMAPK1FFAR4LMNA | |
| SCHEMBL3064272 | 0.71 | THRA (0.57) | THRBTHRAFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | THRB 4/4885THRA 2/4885PCNA 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.